Evidence map›Paper›PMID 16608535›Full record

ArticleBreast cancer research : BCR2006

Tumor-specific expression of alphavbeta3 integrin promotes spontaneous metastasis of breast cancer to bone.

Erica K Sloan, Normand Pouliot, Kym L Stanley, Jenny Chia, Jane M Moseley, Daphne K Hards, Robin L Anderson

Open access · goldAbstract read
In one paragraph

Article in Breast cancer research : BCR, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 152 papers.

0numbers the graph read from it
0cells of the map it votes in
152citing papers in PubMed
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

152 citing papers in PubMed, 270 citations in OpenAlex.

  1. Article
  2. Article
  3. Ultrasmall AuExploration (Beijing, China) · 2026
    Article
  4. Anoikis: To Die or Not to Die?International journal of molecular sciences · 2026
    Review
  5. Article
  6. Review
  7. Exploring bone-tumor interactions through 3DJournal of bone oncology · 2025
    Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Integrins as Drug Targets in Vascular and Related Diseases.International journal of drug discovery and pharmacology · 2024
    Article
  14. Review
  15. Expression of integrin αFuture oncology (London, England) · 2024
    Article
  16. Vasculature organotropism in drug delivery.Advanced drug delivery reviews · 2023
    Review
  17. Article
  18. Article
  19. Article
  20. Review

92 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Erica K SloanPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Normand Pouliot
Kym L Stanley
Jenny Chia
Jane M Moseley
Daphne K Hards
Robin L Anderson
Peter MacCallum Cancer Centre · AUSt Vincents Institute of Medical Research · AU

Funding

Genes important in breast cancer metastasisR01CA090291 · NCI · PETER MACCALLUM CANCER CENTRE · PI ANDERSON, ROBIN L · 2001 to 2003
$405k
NCI NIH HHS R01 CA090291NCI NIH HHS R0I CA 90291
6 · The paper itself

Abstract

introductionStudies in xenograft models and experimental models of metastasis have implicated several beta3 integrin-expressing cell populations, including endothelium, platelets and osteoclasts, in breast tumor progression. Since orthotopic human xenograft models of breast cancer are poorly metastatic to bone and experimental models bypass the formation of a primary tumor, however, the precise contribution of tumor-specific alphavbeta3 to the spontaneous metastasis of breast tumors from the mammary gland to bone remains unclear.

methodsWe used a syngeneic orthotopic model of spontaneous breast cancer metastasis to test whether exogenous expression of alphavbeta3 in a mammary carcinoma line (66cl4) that metastasizes to the lung, but not to bone, was sufficient to promote its spontaneous metastasis to bone from the mammary gland. The tumor burden in the spine and the lung following inoculation of alphavbeta3-expressing 66cl4 (66cl4beta3) tumor cells or control 66cl4pBabe into the mammary gland was analyzed by real-time quantitative PCR. The ability of these cells to grow and form osteolytic lesions in bone was determined by histology and tartrate-resistant acid phosphatase staining of bone sections following intratibial injection of tumor cells. The adhesive, migratory and invasive properties of 66cl4pBabe and 66cl4beta3 cells were evaluated in standard in vitro assays.

resultsThe 66cl4beta3 tumors showed a 20-fold increase in metastatic burden in the spine compared with 66cl4pBabe. A similar trend in lung metastasis was observed. alphavbeta3 did not increase the proliferation of 66cl4 cells in vitro or in the mammary gland in vivo. Similarly, alphavbeta3 is not required for the proliferation of 66cl4 cells in bone as both 66cl4pBabe and 66cl4beta3 proliferated to the same extent when injected directly into the tibia. 66cl4beta3 tumor growth in the tibia, however, increased osteoclast recruitment and bone resorption compared with 66cl4 tumors. Moreover, alphavbeta3 increased 66cl4 tumor cell adhesion and alphavbeta3-dependent haptotactic migration towards bone matrix proteins, as well as their chemotactic response to bone-derived soluble factors in vitro.

conclusionThese results demonstrate for the first time that tumor-specific alphavbeta3 contributes to spontaneous metastasis of breast tumors to bone and suggest a critical role for this receptor in mediating chemotactic and haptotactic migration towards bone factors.

Indexed as

AnimalsBone NeoplasmsBreast NeoplasmsCell AdhesionCell DivisionCell LineEpithelial CellsFemaleHumansIntegrin alphaVbeta3Mammary Glands, AnimalMiceNeoplasm MetastasisSpinal NeoplasmsIntegrin alphaVbeta3

Identifiers

PMID16608535
PMCPMC1557720
OpenAlexW1734622341

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.